TargetBeta
CYP11A1
cytochrome P450 family 11 subfamily A member 1 · also P450SCC, CYP11A · Cytochrome P450 family 11
2 programs in company-led studies act on CYP11A1, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| opevesostat | Merck | phase 3 | 135 running | – | a judged reading |
| CYP11A1 Inhibitor ACE-232rule | Acerand Therapeutics (Hong Kong) | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Prostatic Neoplasms, 2 programs
- Kidney Failure, Chronic, 1 program
- Neoplasms, 1 program
- Prostatic Neoplasms, Castration-Resistant, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 4, 2027opevesostat · Merck · phase 3 · NCT06979596
- Dec 31, 2028CYP11A1 Inhibitor ACE-232 · Acerand Therapeutics (Hong Kong) · phase 1 · NCT06801236
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.